betrixaban and valbenazine

betrixaban has been researched along with valbenazine* in 1 studies

Other Studies

1 other study(ies) available for betrixaban and valbenazine

ArticleYear
2018 New Drug Update.
    The Consultant pharmacist : the journal of the American Society of Consultant Pharmacists, 2018, Apr-01, Volume: 33, Issue:4

    Five new drugs marketed within the last year, which are used for medical problems often experienced by the elderly, have been selected for consideration in this review. The uses and most important properties of these agents are discussed, and a rating for each new drug is determined using the New Drug Comparison Rating system developed by the author (DAH). Advantages, disadvantages, and other important information regarding each new drug are identified and used as the basis for determining the rating. The drugs include an anticoagulant, an antiparkinson agent, an agent for tardive dyskinesia, an agent for psoriasis, and an agent for constipation. The drugs reviewed are betrixaban, safinamide mesylate, valbenazine tosylate, guselkumab, and plecanatide.

    Topics: Aged; Alanine; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Anticoagulants; Antiparkinson Agents; Benzamides; Benzylamines; Constipation; Drug Approval; Humans; Natriuretic Peptides; Psoriasis; Pyridines; Tardive Dyskinesia; Tetrabenazine; Valine

2018